CADI-T1031

**CADI-T1031** is a proprietary immune-modulatory therapeutic protocol developed by Bio-Modeling Systems for chronic fatigue syndrome with immune dysfunction, myalgic encephalomyelitis/chronic fatigue syndrome, and related post-COVID-19 CFS/ME. The program is described as a disease-centric repositioning combination of existing small molecules intended to address persistent low-grade inflammatory immune dysfunction and dysregulated humoral and cellular immune responses. The individual active molecules, molecular targets, formulation, and administration regimen have not been publicly disclosed. Bio-Modeling Systems reports proof-of-concept completion and planned entry into Phase II clinical development. ([bmsystems.org](https://www.bmsystems.org/therapeutic-programs))